Oncology Research

 
Stock Quotes for Oncology Research top ^
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Speculative Growth
Sign-up for csbr investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Distressed
Sign-up for ziop investment picks
  • Industry: Diagnostics & Research
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for avto investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Core
  • Stock Type: Distressed
Sign-up for ziop investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for clvs investment picks
  • Industry: Biotechnology
  • Sector: Healthcare
  • Stock Style: Small Growth
Sign-up for 532545 investment picks
  • Industry: Medical Care
  • Sector: Healthcare
  • Stock Type: Distressed
Sign-up for roix investment picks

 
News Articles for Oncology Research top ^
2013/5/16
Clovis Oncology (NASDAQ:CLVS) announced that three abstracts (ASCO Abstracts #2524, #2585, #2586) highlighting results from three Phase I studies of the company’s two lead compounds will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2013 in Chicago.
Sign-up for Clovis Oncology Announces Clinical Data to be Presented at ASCO Annual Meeting 2013 investment picks
2013/5/7
Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for its first quarter ended March 31, 2013, and provided an update for its clinical development programs .
Sign-up for Clovis Oncology Announces First Quarter 2013 Operating Results investment picks
2013/3/6
Cambridge, Massachusetts Mayor Signs Proclamation Declaring March 6 Colorectal Cancer Awareness Day CAMBRIDGE, Mass.
Sign-up for Sanofi Oncology and Colon Cancer Coalition Join Forces to Raise Awareness of Colorectal Cancer investment picks
2013/2/28
Clovis Oncology , Inc. (NASDAQ:CLVS) today reported financial results for its quarter and year ended December 31, 2012, and provided an update on the expected milestones for its clinical development programs for 2013.
Sign-up for Clovis Oncology Announces 2012 Operating Results and 2013 Objectives investment picks
2013/2/19
Advaxis, Inc ., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the Brown University Oncology Research Group (BrUOG) will be coordinating a Phase 1/2 study of ADXS-HPV in 25 patients with HPV-associated anal cancer.
Sign-up for Advaxis Announces Phase 1/2 Trial of ADXS-HPV in Anal Cancer Conducted by Brown University Oncology Group investment picks
2013/2/14
Clovis Oncology, Inc. (NASDAQ:CLVS) will announce its fourth quarter/year end 2012 financial results on Thursday, February 28, 2013, after the close of the U.S. financial markets.
Sign-up for Clovis Oncology to Announce Fourth Quarter/Year End 2012 Financial Results and Host Webcast Conference Call on February 28 investment picks
2013/2/25
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick J.
Sign-up for Clovis Oncology to Present at the Cowen Health Care Conference in Boston investment picks
2013/4/23
Clovis Oncology, Inc. (Nasdaq:CLVS) will announce its first quarter 2013 financial results on Tuesday, May 7, 2013, before the open of the U.S. financial markets.
Sign-up for Clovis Oncology to Announce First Quarter 2013 Financial Results and Host Webcast Conference Call on May 7 investment picks
2013/5/8
Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Erle T.
Sign-up for Clovis Oncology to Present at the Bank of America Merrill Lynch 2013 Health Care Conference in Las Vegas investment picks
2013/5/2
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) today reported that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted that the application for investigational agent tivozanib did not demonstrate a favorable benefit-to-risk evaluation for the treatment of advanced renal cell carcinoma (RCC) in an adequate and well-controlled trial (13 to 1, 0 abstentions). “While we are disappointed with the outcome of the ODAC vote, we remain confident in the efficacy, safety and tolerability of tivozanib in RCC patients,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO.
Sign-up for AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma investment picks
2013/5/15
BOSTON, May 15, 2013 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Gerald P.
Sign-up for ZIOPHARM Announces Poster Presentation at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting investment picks

Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)
P   Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)
P   Morningstar Stock Analyst Reports (full research on 2,000 stocks)
P   Morningstar Stock and Fund Stewardship Grades
P   Portfolio Manager (advanced with 10 x-ray analyses, including guidance)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Oncology Research
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: On-Year Growth  |  Next: One Holding